Adaptive Immune System: Structure, Function, and Mechanisms

Adaptive Immune System

Introduction to Adaptive Immunity

The adaptive immune system is a highly specialized defense mechanism that enables the body to recognize and eliminate specific pathogens and their products. Unlike the innate immune system, adaptive immunity is characterized by specificity, memory, and the ability to distinguish self from non-self.

• Purpose: To provide targeted and long-lasting protection against pathogens.

• Components: Lymphocytes (B cells and T cells), antigen-presenting cells (APCs), antibodies, and cytokines.

• Organization: Adaptive immune responses are initiated in secondary lymphoid organs such as lymph nodes and the spleen.

Key Attributes of Adaptive Immunity

• Specificity: Targets unique molecular structures (epitopes) on antigens.

• Inducibility: Activated only in response to specific antigens.

• Clonality: Proliferation of lymphocytes with receptors specific to the encountered antigen.

• Unresponsiveness to Self: Tolerates self-antigens to prevent autoimmunity.

• Memory: Generates a faster and stronger response upon re-exposure to the same antigen.

Types of Leukocytes in Adaptive Immunity

Leukocytes, or white blood cells, are central to immune responses. The two main types involved in adaptive immunity are B lymphocytes (B cells) and T lymphocytes (T cells).

• B Cells: Mature in the bone marrow and produce antibodies that neutralize pathogens.

• T Cells: Mature in the thymus and are subdivided into:

  • Helper T cells (CD4+): Direct immune responses via cytokine secretion.

  • Cytotoxic T cells (CD8+): Kill virus-infected or cancerous cells directly.

  • Regulatory T cells: Modulate immune responses to prevent excessive reactions.

Antigen Recognition and Initiation of Adaptive Response

Adaptive immune responses are initiated when antigen-presenting cells (APCs), such as dendritic cells, capture antigens and present them to naïve lymphocytes in secondary lymphoid organs.

• Dendritic Cells: Professional APCs that bridge innate and adaptive immunity by migrating to lymph nodes after antigen capture.

• Secondary Lymphoid Organs: Sites where naïve lymphocytes are activated by APCs (e.g., lymph nodes, spleen, Peyer’s patches).

Antigenic Specificity and Clonal Selection

The adaptive immune system achieves high specificity through unique antigen receptors on B and T cells. Each lymphocyte expresses a receptor with a single specificity. Upon encountering its specific antigen, a lymphocyte undergoes clonal selection, proliferating and differentiating into effector and memory cells.

• Clonal Selection: The process by which only lymphocytes with receptors specific to the antigen are activated and expanded.

• Effector Cells: Actively combat the pathogen (e.g., plasma cells, cytotoxic T cells).

• Memory Cells: Persist long-term to provide rapid responses upon re-exposure.

Mechanisms of Adaptive Immune Response

Helper T Cell Responses (CD4+)

Helper T cells are programmed during priming to produce specific cytokines, tailoring the immune response to the type of pathogen encountered.

• Th1 Cells: Produce IFN-γ, activate macrophages for intracellular pathogens (cell-mediated immunity).

• Th2 Cells: Produce IL-4 and IL-5, stimulate B cells for antibody production and anti-parasite responses (humoral immunity).

• Th17 Cells: Produce IL-17, recruit neutrophils for extracellular bacteria and fungi.

Cytotoxic T Cell Responses (CD8+)

Cytotoxic T cells kill infected or abnormal cells via two main pathways:

• Perforin-Granzyme Pathway: Releases proteins that induce apoptosis in target cells.

• CD95 Pathway: Engages death receptors on target cells to trigger apoptosis.

B Cell Responses and Antibody Production

B cells, upon activation (often with T cell help), differentiate into plasma cells that secrete antibodies. Antibodies neutralize pathogens, promote phagocytosis, activate complement, and mediate other effector functions.

• Antibody Functions: Neutralization, opsonization, agglutination, complement activation, and antibody-dependent cellular cytotoxicity (ADCC).

Types of Acquired Immunity

Adaptive immunity can be acquired naturally or artificially, and can be active or passive.

	Active	Passive
Naturally Acquired	Antigens enter the body naturally; body induces antibodies and specialized lymphocytes.	Antibodies pass from mother to fetus via placenta or to infant via mother’s milk.
Artificially Acquired	Antigens are introduced in vaccines; body produces antibodies and specialized lymphocytes.	Preformed antibodies in immune serum are introduced by injection.

Immunological Memory

Memory cells generated during the primary immune response enable a more rapid and robust secondary response upon re-exposure to the same antigen. This principle underlies the effectiveness of vaccines.

• Primary Response: Slow, produces small amounts of antibody.

• Secondary Response: Rapid, produces large amounts of antibody, mainly IgG.

Immune Pathology and Tolerance

While the adaptive immune system is essential for defense, inappropriate or excessive responses can lead to immune pathology, including autoimmune diseases (e.g., Type I diabetes, rheumatoid arthritis, lupus).

• Tolerance: Mechanisms that prevent immune responses against self-antigens.

• Immune Pathology: Damage caused by immune responses, sometimes exceeding the harm caused by the pathogen itself.

Summary Table: Main Steps in Adaptive Immune Response

Step	Description
1. Antigen Presentation	APCs present antigen to naïve T cells in secondary lymphoid organs.
2. Lymphocyte Activation	Naïve lymphocytes are activated by their specific antigen.
3. Clonal Expansion	Activated lymphocytes proliferate and differentiate into effector and memory cells.
4. Effector Function	Effector cells eliminate the pathogen via cytotoxicity or antibody production.
5. Memory Formation	Memory cells persist for rapid response upon re-exposure.

Additional info: The adaptive immune system is a cornerstone of modern immunology and underlies the principles of vaccination, immune memory, and the development of immunotherapies for infectious and autoimmune diseases.